Karyopharm Therapeutics Inc. announced its fourth quarter and full year 2025 financial results, reporting total revenue of $146.1 million for the year and providing full-year 2026 total revenue guidance of $130 million to $150 million. The company highlighted upcoming clinical milestones, including top-line data from its Phase 3 SENTRY trial in myelofibrosis expected in March 2026.
Key takeaways
Total revenue for the full year ended December 31, 2025 was $146.1 million, compared to $145.2 million for the prior year.
U.S. XPOVIO net product revenue for the full year 2025 was $114.9 million, compared to $112.8 million for the prior year.
The company provided full-year 2026 total revenue guidance of $130 million to $150 million, including U.S. XPOVIO net product revenue guidance of $115 million to $130 million.
Top-line data from the Phase 3 SENTRY trial in myelofibrosis is expected in March 2026.
Top-line data from the Phase 3 XPORT-EC-042 trial in endometrial cancer is expected in mid-2026.
Cash, cash equivalents, restricted cash and investments as of December 31, 2025 totaled $64.1 million, compared to $109.1 million as of December 31, 2024.